BC
HAE icon

Bridgefront Capital’s Haemonetics HAE Stock Holding History

Bridgefront Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$809K Buy
14,363
+4,133
+40% +$269K 0.2% 161
2025
Q4 		$820K Buy
10,230
+5,492
+116% +$369K 0.21% 164
2025
Q3 		$231K Buy
+4,738
New +$293K 0.07% 480
2025
Q2 		– Sell
-8,178
Closed -$520K – 706
2025
Q1 		$520K Buy
8,178
+3,113
+61% +$212K 0.15% 240
2024
Q4 		$395K Buy
+5,065
New +$407K 0.13% 272
2024
Q2 		– Sell
-3,835
Closed -$327K – 562
2024
Q1 		$327K Buy
+3,835
New +$301K 0.25% 158
2021
Q2 		– Sell
-3,574
Closed -$397K – 722
2021
Q1 		$397K Buy
+3,574
New +$442K 0.12% 330

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridgefront Capital's HAE Position: Q1 2026 in Review

Bridgefront Capital increased its Haemonetics (HAE) stake by 40% in Q1 2026, buying an estimated $269K and bringing the position to 14,363 shares worth $809K. The position accounts for 0.2% of the portfolio, ranked #161.

Bridgefront Capital first reported a position in HAE in Q1 2021 and has held it in 7 quarters since. The position peaked at $820K in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Bridgefront Capital held 14,363 shares of Haemonetics worth $809K as of Q1 2026.
  • Bridgefront Capital bought 4,133 Haemonetics shares in Q1 2026, an estimated $269K.
  • Haemonetics made up 0.2% of Bridgefront Capital's portfolio in Q1 2026, its #161 holding.
  • Bridgefront Capital first reported a position in Haemonetics in Q1 2021 and has held it in 7 quarters since.
  • Bridgefront Capital's Haemonetics position peaked at $820K in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.